Blood Reviews
Volume 20, Issue 3 , Pages 173-178 , May 2006

Duration of anticoagulation: decision making based on absolute risk

  • David Keeling

      Affiliations

    • Corresponding Author InformationTel.: +44 1865 225318; fax: +44 1865 225608.

References 

  1. Prins M, et al. Long-term treatment of venous thromboembolic disease. Thrombosis and Haemstasis. 1999;82:892–898
  2. Vink R, et al. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost. 2003;1(12):2523–2530
  3. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism; a controlled trial. Lancet. 1960;1:1309–1312
  4. Schulman S, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group [see comments]. N Engl J Med. 1995;332(25):1661–1665
  5. Schulman S, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336(6):393–398
  6. Kearon C, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901–907
  7. Baglin T, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–526
  8. Prandoni P. Risk factors of recurrent venous thromboembolism: the role of residual vein thrombosis. Pathophysiol Haemost Thromb. 2003;33(5-6):351–353
  9. Prandoni P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955–960
  10. Fattorini A, et al. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost. 2002;88(1):162–163
  11. Palareti G, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87(1):7–12
  12. Galli M, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–1832
  13. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. it N Engl J Med, 1997. 337(10): p. 657–62.
  14. Buller HR, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695–1702
  15. Simonneau G, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med. 1997;337(10):663–669
  16. Anderson FJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–938
  17. Heit J, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445–453
  18. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386–1389
  19. Douketis J, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279(6):458–462
  20. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002;88(3):407–414
  21. Palareti G, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423–428
  22. van der Meer FJ, et al. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76(1):12–16
  23. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893–900
  24. Lee AY, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153

PII: S0268-960X(05)00044-5

doi: 10.1016/j.blre.2005.09.001

Blood Reviews
Volume 20, Issue 3 , Pages 173-178 , May 2006

Article Tools